Conatus Pharmaceuticals Inc. (CNAT)

[staccani]

GILD vs CNAT positioning in Nash Cirrhosis (attached the link to Child Pugh/MELD score correlation)

GILD has just started 2 trials in advanced fibrosis and compensated cirrhosis named Stellar 3 and Stellar 4 respectively.
Stellar 3 has a key exclusion criteria a CP score >6 and Stellar 4 a CP score > 7 and any decompensation event. Basically it is positioning itself at the beginning of the spectrum of the sick patients , ie targeting Child Pugh A group in both cases , with 100% probability survival at 1 year.

CNAT is on the other hand targeting in ENCORE PH patients with HPVG > 12mmg and up to Child Pugh score of 10, which normally include up to MELD score to 15, ie compensated patients at high risk of developing decompensation or early decompensated.
In ENCORE LF it will be targeting decompensated patients with MELD score at or above 15, which normally include Child Pugh C patients as well.
From the above it is clear that CNAT Emricasan will be treating the sickest patients, and it does not have competition at the moment in this segment



https://www.researchgate.net/figure/6150278_fig1_Figure-1-Correlation-between-Child-Turcotte-Pugh-Child-and-model-for-end-stage-liver